Common types of targeted therapy for chronic lymphocytic leukemia (CLL) are monoclonal antibodies, BTK (Bruton’s tyrosine kinase) inhibitors, and PI3K inhibitors. The details are as follows: 1. monoclonal antibodies. This is a type of targeted therapy that uses laboratory-made antibodies. They attach to proteins on CLL cells and kill the cells or stop them from growing. Common monoclonal antibodies include: Rituximab, Ofatumumab, and others. 2. BTK (Bruton’s tyrosine kinase) inhibitors. These drugs block BTK in leukemia cells. BTK inhibitors used in the treatment of CLL include: ibrutinib, akalabrutinib, and others. 3. PI3K inhibitors. PI3K is a protein that helps cells grow and survive. These drugs block the protein that kills CLL cells and prevents them from growing. Common drugs in this class include Duvelisib. Treatment varies for each patient depending on their condition. If diagnosed with chronic leukemia, a specific treatment plan should be developed under the guidance of a clinician.